Announced Fri, 29 May · 13:56 IST

Annual Secretarial Compliance Report 31.03.2026.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.9%1-day move
₹27.26
prior close
₹27.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0+0.0+0.0+2.9+5.8+6.3+6.0+7.1+10.1+8.0+49.3
Up moveDown movePending
AI summary

ANG Lifesciences India Limited has received its Annual Secretarial Compliance Report for FY 2025-26 from Anil Negi & Company. The company generally complied with SEBI regulations but reported three minor deviations: (1) delay in submission of Reconciliation of Share Capital Audit for Q3 Dec 2025, (2) delay in payment of Annual Listing Fees for FY 2024-25 and FY 2025-26 resulting in interest of ₹41,951, and (3) delay in submission of shareholding pattern for Q3 Dec 2025 with a fine of ₹54,280 pending. The company has subsequently made all required compliances and paid the listing fees with interest. Most compliance parameters including secretarial standards, board processes, insider trading norms, and related party transactions were found satisfactory with no disqualification of directors or actions by SEBI or stock exchanges.

Likely market impact

Minor compliance lapses with no material impact on shareholders. The company has cleared all delayed filings and paid dues, suggesting operational normalcy despite administrative delays. Fines totaling approximately ₹96,231 are relatively small.